252 related articles for article (PubMed ID: 31479631)
1. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
Zhou W; Li Y; Song J; Li C
Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
3. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
4. Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence.
Furet P; Salem B; Mesrouze Y; Schmelzle T; Lewis I; Kallen J; Chène P
Bioorg Med Chem Lett; 2019 Aug; 29(16):2316-2319. PubMed ID: 31235263
[TBL] [Abstract][Full Text] [Related]
5. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
[TBL] [Abstract][Full Text] [Related]
6. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive
Nouri K; Azad T; Ling M; Janse van Rensburg HJ; Pipchuk A; Shen H; Hao Y; Zhang J; Yang X
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635084
[TBL] [Abstract][Full Text] [Related]
7. An Early Association between the α-Helix of the TEAD Binding Domain of YAP and TEAD Drives the Formation of the YAP:TEAD Complex.
Bokhovchuk F; Mesrouze Y; Meyerhofer M; Zimmermann C; Fontana P; Erdmann D; Jemth P; Chène P
Biochemistry; 2020 May; 59(19):1804-1812. PubMed ID: 32329346
[TBL] [Abstract][Full Text] [Related]
8. Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling.
Holden JK; Crawford JJ; Noland CL; Schmidt S; Zbieg JR; Lacap JA; Zang R; Miller GM; Zhang Y; Beroza P; Reja R; Lee W; Tom JYK; Fong R; Steffek M; Clausen S; Hagenbeek TJ; Hu T; Zhou Z; Shen HC; Cunningham CN
Cell Rep; 2020 Jun; 31(12):107809. PubMed ID: 32579935
[TBL] [Abstract][Full Text] [Related]
9. Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex.
Pobbati AV; Rubin BP
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352993
[TBL] [Abstract][Full Text] [Related]
10. Structure-based derivation and optimization of YAP-like coactivator-derived peptides to selectively target TEAD family transcription factors by hydrocarbon stapling and cyclization.
He B; Wu T; He P; Lv F; Liu H
Chem Biol Drug Des; 2021 Jun; 97(6):1129-1136. PubMed ID: 33283479
[TBL] [Abstract][Full Text] [Related]
11. Leveraging Hot Spots of TEAD-Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling.
Zhao B; Pobbati AV; Rubin BP; Stauffer S
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111340
[TBL] [Abstract][Full Text] [Related]
12. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.
Mesrouze Y; Bokhovchuk F; Meyerhofer M; Fontana P; Zimmermann C; Martin T; Delaunay C; Erdmann D; Schmelzle T; Chène P
Elife; 2017 Apr; 6():. PubMed ID: 28430104
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors.
Holden JK; Cunningham CN
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29558384
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and Structural Characterization of a Peptidic Inhibitor of the YAP:TEAD Interaction That Binds to the α-Helix Pocket on TEAD.
Mesrouze Y; Gubler H; Villard F; Boesch R; Ottl J; Kallen J; Reid PC; Scheufler C; Marzinzik AL; Chène P
ACS Chem Biol; 2023 Mar; 18(3):643-651. PubMed ID: 36825662
[TBL] [Abstract][Full Text] [Related]
15. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
Zagiel B; Melnyk P; Cotelle P
Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
[TBL] [Abstract][Full Text] [Related]
16. Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy.
Bokhovchuk F; Mesrouze Y; Izaac A; Meyerhofer M; Zimmermann C; Fontana P; Schmelzle T; Erdmann D; Furet P; Kallen J; Chène P
FEBS J; 2019 Jun; 286(12):2381-2398. PubMed ID: 30903741
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics simulations study of influence of Tyr422Ala mutation on transcriptional enhancer activation domain 4 (TEAD4) and transcription co-activators complexes.
Niu RJ; Zheng QC; Zhang HX
J Theor Biol; 2019 Jul; 472():27-35. PubMed ID: 30978352
[TBL] [Abstract][Full Text] [Related]
18. Targeting YAP/TAZ-TEAD protein-protein interactions using fragment-based and computational modeling approaches.
Kaan HYK; Sim AYL; Tan SKJ; Verma C; Song H
PLoS One; 2017; 12(6):e0178381. PubMed ID: 28570566
[TBL] [Abstract][Full Text] [Related]
19. Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket.
Kim J; Jin H; Kim J; Cho SY; Moon S; Wang J; Mao J; No KT
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791396
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
Elife; 2022 Nov; 11():. PubMed ID: 36398861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]